Background {#Sec1}
==========

Antimicrobial resistance is a major global health concern, and, of the Gram-positive bacteria, drug-resistant *Staphylococcus aureus* is a serious threat \[[@CR1], [@CR2]\]. *S. aureus* causes a wide range of infections commonly involving the skin, soft tissue, bone, joints, and infections associated with indwelling catheters or prosthetic devices \[[@CR3]\]. In addition, *S. aureus* is a leading cause of bacteremia in industrialized nations \[[@CR4], [@CR5]\]. Although methicillin-resistant *S. aureus* (MRSA) bacteremia incidence has decreased over the past decade \[[@CR3]\], MRSA remains associated with poorer clinical outcomes compared with methicillin-sensitive *S. aureus* (MSSA) \[[@CR6]\]. *S. aureus* bacteremia (SAB) often causes metastatic infections such as infective endocarditis (IE), septic arthritis, and osteomyelitis \[[@CR3]\]. Moreover, SAB can lead to complications such as sepsis and septic shock \[[@CR6]\]. Taken together, these issues make SAB particularly challenging to treat.

Choice and timing of antibacterial therapy greatly affect treatment outcomes in SAB \[[@CR6]\]. For SAB caused by MSSA, β-lactam therapy is considered the gold standard \[[@CR6], [@CR7]\]. For MRSA, the 2011 Infectious Diseases Society of America guidelines recommend treatment with vancomycin or daptomycin \[[@CR3], [@CR8]\]. However, each antimicrobial agent has limitations. Several issues restrict the utility of vancomycin, including slow bactericidal activity, low tissue penetration, and increasing reports of resistance and failure \[[@CR9]--[@CR11]\]. While daptomycin is effective against MRSA bacteremia, treatment-emergent nonsusceptibility is concerning \[[@CR12]--[@CR14]\], and evidence suggests prior vancomycin treatment may encourage daptomycin resistance in *S. aureus* \[[@CR15], [@CR16]\]. Given the substantial morbidity and mortality associated with SAB \[[@CR6]\] and the limitations of currently approved treatments, there is a need to identify alternative agents for the treatment of MRSA bacteremia. Time to effective treatment is largely dependent on pathogen identification \[[@CR17]\]. Delays in diagnosing and treating SAB lead to poorer clinical outcomes \[[@CR18]\]. Standard microbial identification techniques take between 48 and 72 h, while recently developed rapid diagnostic tests provide data within 3 h of collection \[[@CR19]\]. By enabling optimized antimicrobial therapy, rapid diagnostic tests may lower mortality, hospitalization, and costs \[[@CR20]\]. This review discusses the global incidence and prevalence, diagnostic methods, and current management strategies for SAB. We also briefly discuss another key part of MRSA infection management---prevention; however, an in depth discussion is beyond the scope of this review.

Prevalence of MRSA bacteremia {#Sec2}
=============================

The prevalence of MRSA infections, especially bacteremia, differs around the world. In 2014, the percentage of invasive MRSA isolates in Europe ranged from 0.9% in the Netherlands to 56% in Romania, with a population-weighted mean of 17.4% \[[@CR21]\]. MRSA prevalence exhibits a north--south variation in Europe, with a higher proportion of resistant isolates in southern countries compared with northern countries \[[@CR21]\]. Even though the proportion of MRSA isolates in Europe has decreased over time, 7 of the 29 European Union countries still report 25% or more of invasive *S. aureus* isolates as MRSA \[[@CR21]\].

A review of 15 studies shows between 13 and 74% of worldwide *S. aureus* infections are MRSA \[[@CR22]\]. The prevalence of *S. aureus* infections in countries of South and East Asia and the Western Pacific is difficult to ascertain; however, publications and national surveillance data from these regions identify *S. aureus* as a significant pathogen, with MRSA incidence ranging from 2.3 to 69.1% \[[@CR1], [@CR23]\]. In 2005, invasive MRSA infections in the US occurred at a rate of 31.8 per 100,000 people after adjustment for age, race, and gender, and 75% of these invasive MRSA infections involved SAB \[[@CR24]\]. This is higher than the MRSA bacteremia rates reported in Canada from 2000 to 2004, which were 2.1, 1.6, and 3.6 per 100,000 people for Calgary, Victoria, and Sherbrooke, respectively \[[@CR25]\]. Within a 1-year period (2011--2012), 12.3% of all healthcare-associated infections in Europe were caused by *S. aureus* \[[@CR26]\]. In Cyprus, Italy, Portugal, and Romania, more than 60% of healthcare-associated *S. aureus* infections were identified as MRSA \[[@CR26]\].

The origin of SAB cases---community-acquired, hospital-acquired, or healthcare-associated community onset---has been changing. The incidence of invasive MRSA infections in the US has decreased (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR27], [@CR28]\], with healthcare-associated community-onset infections now making up the greatest proportion. Community-acquired MRSA bacteremia, including healthcare-associated community-onset, has superseded hospital-acquired MRSA bacteremia globally. Patients with healthcare-associated community-onset MRSA infections frequently have comorbidities, such as diabetes, decubitus, ulcers, chronic renal disease, prior stroke, or dementia \[[@CR28]\]. Data from Canada, Australia, and Scandinavia show an increase in the rate of MRSA bacteremia between 2000 and 2008 (*P* = 0.035), mainly caused by an increase in community-acquired infections (*P* = 0.013). These findings indicate that community-acquired MRSA infections remain a threat.Fig. 1The national estimated number of MRSA infections in the US, stratified by infection setting. Adapted from data reported by the Center for Disease Control and Prevention \[[@CR27]\] and Dantes et al. \[[@CR28]\]. *MRSA* methicillin-resistant *S. aureus*

MRSA molecular epidemiology {#Sec3}
===========================

Different strains are responsible for hospital- and community-acquired MRSA infections and can be identified using molecular typing methods such as pulsed field gel electrophoresis (PFGE) or multilocus sequence typing \[[@CR29], [@CR30]\]. These typing methods can distinguish strains based on the genes encoding the staphylococcus protein A or the staphylococcal chromosomal cassette (SCC) *mec* \[[@CR29]\]. In the US, hospital-acquired MRSA infections are generally caused by the PFGE USA100 or USA200 strains, whereas community-acquired MRSA infections are commonly associated with the USA300 or USA400 strains \[[@CR30]\]. Internationally, the ST239 strain is a common cause of hospital-acquired MRSA, but is rarely reported in the US \[[@CR31], [@CR32]\]. Methicillin resistance has been linked to clonal variants in the SCC*mec* gene \[[@CR33]\]. Five different subtypes of SCC*mec* exist, which vary in size from about 20 to 68 kb \[[@CR33]\]. Hospital-acquired MRSA strains often contain SCC*mec* subtype II \[[@CR30], [@CR34]\]. In contrast, SCC*mec* subtype IV, rarely found in hospital-acquired MRSA strains, is more prevalent in community-acquired MRSA strains globally \[[@CR30], [@CR34]\].

Other molecular features distinguish community-acquired from hospital-acquired strains of MRSA. Panton-Valentine leucocidin (PVL) is a powerful exotoxin that induces lysis of leukocytes, particularly neutrophils \[[@CR35], [@CR36]\]. Community-acquired strains, including the USA300 strain, usually carry the gene for PVL, whereas it is rare in hospital-acquired strains \[[@CR30], [@CR37]\]. The USA300 PVL-positive strain is not prevalent in Western Europe, where other PVL-positive strains, including ST80, are more commonly reported \[[@CR38]\]. PVL-positive *S. aureus* strains have been responsible for outbreaks of necrotizing pneumonia and invasive skin disease; however, the role of PVL in disease severity is not clear \[[@CR39]\]. PVL is not the only toxin produced by MRSA. Different strains produce a range of toxins, including toxic shock syndrome toxin-1 (TSST1), staphylococcal enterotoxin B or C, α-hemolysin, and the phenol-soluble modulins (PSMs) \[[@CR40], [@CR41]\]. The expression of several toxins, including α-hemolysin and PSMs, is controlled by the *agr* regulatory system, which is more likely to be present in community- than hospital-acquired strains \[[@CR40]\]. Overall, the expression of toxin-producing genes is higher in community- than hospital-acquired MRSA strains and community-acquired strains tend to be more virulent \[[@CR40], [@CR42]\]. In patients with MRSA bacteremia, the presence of staphylococcal enterotoxin- and TSST1-producing genes is associated with a significant increase in the risk of mortality \[[@CR41]\].

MRSA colonization {#Sec4}
=================

About one-third of the general population is colonized with *S. aureus*, and the pooled prevalence of MRSA colonization is 1.3% (95% confidence interval \[CI\] 1.04--1.53%) \[[@CR43]\]. MRSA colonization varied between studies depending on the methodology used. For example, when cultures were taken at the time of hospital admission or outpatient assessment, prevalence of colonization with community-acquired MRSA was 1.8%, but when samples were taken from individuals outside of the healthcare environment, it was 0.76% \[[@CR43]\]. While the percentage of the US population with *S. aureus* nasal colonization has decreased over time, the proportion of people colonized with MRSA has increased \[[@CR44]\]. Risk factors for colonization with MRSA in US females were age ≥60 years, diabetes, and poverty-level household income, whereas in US males the only significant risk factor was healthcare exposure \[[@CR44]\]. Other studies identify chronic illness, injected drug use, recent hospitalization or outpatient visit, recent antibiotic use, and contact with an MRSA-infected person as risk factors.

While the most common site of MRSA colonization is the anterior nares \[[@CR45]\], *S. aureus* (including MRSA) may also be present in the throat, axilla, rectum, groin, or perineum, and frequently colonizes more than one site \[[@CR46], [@CR47]\]. Recent studies suggest colonization of the throat is more prevalent than of the nose, and checking only the nose would fail to detect a significant portion of colonized persons \[[@CR47], [@CR48]\]. Regarding nasal carriage of *S. aureus*, about 20% of the population are persistently colonized with one strain, about 60% are intermittent carriers of varying strains, and the rest of the population never exhibit nasal colonization \[[@CR49]\]. Hospital-acquired MRSA infections generally arise from persistent carriers undergoing antibiotic therapy or from intermittent carriers \[[@CR45]\]. Both intermittent and persistent MRSA nasal colonization significantly increase the risk of developing an MRSA-invasive infection, including bacteremia (hazard ratios of 22.8 and 36.8, respectively; *P* value for both compared to noncarriers is \<0.001) \[[@CR50]\]. In a 2-year period, 21% of persistent and 13% of intermittent carriers developed an invasive infection \[[@CR50]\].

To understand the relationship between colonizing and infecting strains, investigators analyzed patients admitted to the emergency department for closed skin abscesses \[[@CR47]\]. The majority (\~90%) were colonized with the *S. aureus* strain isolated from the infection, and 31% of these patients were colonized with an additional strain. Having two MRSA strains was uncommon (4.1%), but MRSA + MSSA or two MSSA strains were present in 20.4 and 22.2% of patients, respectively \[[@CR47]\]. Concordance of the colonizing and infecting strain was also seen in about 82% of SAB patients \[[@CR51]\].

Detection and diagnosis of MRSA strains {#Sec5}
=======================================

Identifying the causative organism can be challenging in SAB, especially for resistant strains. Traditional culture and susceptibility testing for MRSA takes between 48 and 72 h, including a 16- to 24-h incubation and another 16 to 24 h to complete the susceptibility tests \[[@CR19]\]. Recent advances in molecular and nonmolecular testing methods greatly reduced the time required to detect MRSA \[[@CR19]\]. These rapid and sensitive screening assays could help to improve infection control and decrease costs. With a rapid test, Bauer et al. \[[@CR20]\] observed bacteremia patients diagnosed with MRSA had a shorter length of stay and lower overall hospital costs, and for patients with MSSA, the switch from empiric to targeted therapy was 1.6 days shorter. Use of rapid molecular diagnostic tests rather than conventional methods is also associated with a significantly lower mortality risk for patients with bloodstream infections (odds ratio (OR) \[95% CI\] 0.66 \[0.54--0.80\]), including those caused by Gram-positive organisms (OR \[95% CI\] 0.73 \[0.55--0.97\]) \[[@CR52]\]. Combining rapid molecular testing with an antibiotic stewardship program can further reduce the risk of mortality \[[@CR52]\]. Individual hospitals deciding which test to implement must consider the specificity, sensitivity, price, turnaround time, and expertise required for each test \[[@CR19], [@CR53]\].

An adaptation to the traditional culture method is the use of chromogenic agar, which produces a color reaction in the bacterial cultures \[[@CR19]\]. These media also contain antibiotics that only allow resistant bacteria to grow \[[@CR19]\]. Thus, MRSA can be detected in 20 to 26 h \[[@CR19]\]. A meta-analysis of performance characteristics of available chromogenic media tests reported a pooled sensitivity estimate of 78.3% after 18 to 24 h and of 87.6% after 48 h (Table [1](#Tab1){ref-type="table"}), and the pooled specificity estimate was almost 97% at 18 to 24 h and 94% at 48 h \[[@CR53]\]. Sensitivity at 18 to 24 h was significantly lower than at 48 h, but the sensitivity at 48 h was comparable between chromogenic media and traditional culture methods (86.9%) \[[@CR53]\]. The 18- to 24-h specificity of chromogenic media for detecting MRSA was significantly higher than the specificity of traditional culture (Table [1](#Tab1){ref-type="table"}) \[[@CR53]\]. In clinical practice, the use of chromogenic media has been shown to reduce the time to targeted MRSA treatment by 12 h \[[@CR17]\].Table 1Sensitivity and specificity of different MRSA testing methodologies based on pooled dataMRSA testing modalityNumber of studiesSensitivity, % (95% CI)Specificity, % (95% CI)Culture 48 h786.9 (74.7--93.7)89.7 (77.7--95.6)^a^Chromogenic media, 18--24 h2878.3 (71.0--84.1)^a,b^98.6 (97.7--99.1)^b,c^Chromogenic media, 48 h2487.6 (82.1--91.6)94.7 (91.6--96.8)PCR1592.5 (87.4--95.9)97.0 (94.5--98.4)Adapted from data presented in Luteijn et al. \[[@CR53]\]*Abbreviations*: *CI* confidence interval, *MRSA* methicillin-resistant *S. aureus*, *PCR* polymerase chain reaction^a^ *P* \<0.05 vs PCR^b^ *P* \<0.05 vs chromogenic media at 48 h^c^ *P* \< 0.05 vs culture at 48 h

Another innovation in MRSA detection is the development of real-time polymerase chain reaction (PCR) tests capable of detecting genes specific to *S. aureus* \[[@CR19]\]. To distinguish MRSA strains from MSSA or methicillin-resistant coagulase-negative staphylococci, PCR methods target a portion of DNA where the MRSA-specific SCC*mec* gene meets the *S. aureus orfX* gene \[[@CR19]\]. The PCR tests can be performed directly on samples obtained from blood or a nasal or wound swab, and results are usually available within 1 to 3 h \[[@CR19]\]. In clinical practice, however, turnaround times from sampling to a result are typically longer because of the time required to transport samples, conduct the test, and report the results \[[@CR54]\]. Nevertheless, the overall time is generally much shorter with PCR-based assays than with chromogenic media culture \[[@CR54]\]. In addition, PCR tests showed pooled estimates for sensitivity and specificity of 92.5 and 97.0%, respectively, in the meta-analysis mentioned above \[[@CR53]\]. Furthermore, the sensitivity of PCR was significantly higher than that of chromogenic media, and the specificity was significantly higher than that of traditional culture \[[@CR53]\]. Relative to MRSA detection by chromogenic agar, PCR reduced the overall duration of patient isolation and number of days patients were inappropriately isolated during their hospital stay \[[@CR54]\].

Another approach to MRSA detection is to use immunochromatographic tests. These tests use antibodies toward specific bacterial proteins to generate a visible reaction in the test medium if that protein is present in the sample \[[@CR19], [@CR55]\]. One type of immunochromatographic test is the latex agglutination test, which uses a monoclonal antibody against PBP2a, a protein produced by the *mecA* gene \[[@CR19]\]. If PBP2a is present in the sample, the latex particles sensitized by the antibody clump together, forming a readily visible agglutination \[[@CR19]\]. The latex agglutination test has sensitivity of 97% for correctly identifying MRSA and a specificity of 100% for distinguishing MRSA from MSSA, even in low-level samples \[[@CR19], [@CR56]\]. Another PBP2a-antibody test (Clearview Exact) has identical performance characteristics in low-level MRSA samples (sensitivity 97% and specificity 100%) \[[@CR56]\], but requires fewer steps than the latex agglutination test \[[@CR57]\]. This test takes less than 6 minutes to complete, and results appear as colored lines on test strips \[[@CR57]\]. The BinaxNOW *Staphylococcus aureus* Test differentiates *S. aureus* from coagulase-negative staphylococci and other Gram-positive cocci directly from positive blood culture bottles \[[@CR55]\]. This test takes less than 30 minutes and has a sensitivity of 95.8% and a specificity of 99.6% \[[@CR55]\]. While this test does not identify MRSA specifically, it can rule out other staphylococci and is inexpensive \[[@CR55]\]. Because of the low cost and speed of results, it may be a useful test to undertake before sending samples for PCR testing \[[@CR55]\].

MRSA treatments and outcomes {#Sec6}
============================

Although MRSA bacteremia must always be taken seriously, some clinical characteristics place patients at risk of a complicated course requiring prolonged treatment (Table [2](#Tab2){ref-type="table"}) \[[@CR7], [@CR58]\]. *S. aureus* bacteremia is considered uncomplicated when the infection meets the following requirements: a catheter-related infection where the catheter is removed; negative result on follow-up blood culture; fever resolution within 72 h; no abnormal findings on transesophageal echocardiogram; no implanted prosthetic material; and no symptoms of a metastatic infection \[[@CR8], [@CR58]\]. Complicated bacteremia is diagnosed when any of these criteria are not met. In general, antistaphylococcal treatment should be continued for about 14 days in those with uncomplicated bacteremia, and for 4 to 6 weeks in those with complicated SAB \[[@CR8], [@CR59]\].Table 2Demographic and clinical characteristics associated with more severe SABCharacteristicImpactCommunity-acquired infectionTends to metastasizeFemale genderIncreased risk of mortality vs malesPositive blood cultures present for longer than 48 hComplicated course (including metastatic infections)Persistent fever at 72 hComplicated courseTime for blood culture to turn positiveComplicated course (including metastatic infections and increased risk of mortality)Lack of identifiable focusAggravates and prolongs SABSkin lesions suggestive of acute systemic infectionComplicated courseImplanted prosthetic deviceComplicated course (including increased risk of mortality and relapse)Immunosuppression and HIVAggravates and prolongs SABRenal failureIntravascular complicationsSolid tumorsIntravascular complicationsAPACHE II score \>7Complicated course (including increased risk of septic shock and mortality)CURB-65 score \>3Complicated course (including increased risk of septic shock and mortality)Neurologic complicationsIncreased risk of mortalityCardiac complicationsIncreased risk of mortalitySeptic thrombophlebitisProlonged clinical courseMRSA pneumoniaComplicated course (including increased risk of septic shock and mortality)Portions of this table were reproduced with permission from Table [1](#Tab1){ref-type="table"} in Keynan and Rubinstein \[[@CR7]\] and additional information was adapted from Corey \[[@CR58]\]Abbreviations: *APACHE* Acute Physiology and Chronic Health Evaluation, *CURB-65* confusion, urea, respiratory rate, blood pressure, and age 65, *HIV* human immunodeficiency virus, *MRSA* methicillin-resistant *S. aureus*, *SAB S. aureus* bacteremia

An important first step in MRSA bacteremia management is to identify and eliminate the source of infection \[[@CR8], [@CR60]\]. If an intravascular catheter is the source, it should be removed as soon as possible after diagnosis; any wounds should be debrided \[[@CR8], [@CR60]\]. In patients with short- or long-term catheter-related MRSA infection who develop suppurative thrombophlebitis, remove the catheter and treat as complicated bacteremia; anticoagulation with heparin has been reported, but evidence to support a recommendation is lacking \[[@CR61]\]. Patients with MRSA IE and a prosthetic valve should be evaluated for valve replacement surgery, as should those with native valve IE if the infection is extensive or complicated \[[@CR8]\]. When bacteremia is persistent, hidden sources of infection should be identified using MRI or CT imaging and removed by drainage or surgical debridement \[[@CR8]\].

Empirical treatment decisions in MRSA bacteremia require consideration of the prevalence and resistance profile of local strains, risk factors for a complicated clinical course, presence of comorbidities, concurrent interventions, and response to prior antibiotics \[[@CR59]\]. Current US and European treatment recommendations are summarized in Table [3](#Tab3){ref-type="table"} \[[@CR8], [@CR59], [@CR60], [@CR62], [@CR63]\]. For most cases of MRSA bacteremia, vancomycin or daptomycin is the recommended treatment \[[@CR64]\]. The choice of antibiotic may also depend on if the bacteremia is secondary to another infection. For example, daptomycin, although indicated for treatment of SAB, is contraindicated for SAB originating from pneumonia since pulmonary surfactants inactivate it \[[@CR3]\]. Vancomycin poorly penetrates lung tissue; thus, linezolid or clindamycin are recommended if the strain is susceptible \[[@CR8]\]. Reports of MRSA isolates resistant or nonsusceptible to currently available antibiotics, including vancomycin \[[@CR11], [@CR59]\], daptomycin \[[@CR65]\], and ceftaroline \[[@CR66]\], as well as multidrug-resistant MRSA clones, are a concerning trend \[[@CR67]\]. These data highlight the importance of early identification of MRSA and susceptibility to identify the optimal antibiotic.Table 3Treatment recommendations for MRSA bacteremiaConditionIDSA \[[@CR8]\]ESCMID/ISC/ESC \[[@CR59], [@CR60], [@CR62], [@CR63]\]Uncomplicated bacteremiaVancomycin or daptomycin 6 mg/kg/dose IV once daily for 2 weeksVancomycin doses to trough plasma concentration of 15--20 mg/L or teicoplanin if nephrotoxicity is a concern (daptomycin if vancomycin is poorly tolerated) for 10--14 days Consider switching to linezolid PO in patients with a rapid response and negative cultures after catheter removalComplicated bacteremiaVancomycin or daptomycin 6 mg/kg/dose IV once daily for 4--6 weeks, depending on extent of infectionVancomycin, but switch to daptomycin if there is poor response or use daptomycin first-line in patients with life-threatening infection, renal impairment, previous glycopeptide use, or vancomycin resistance or reduced susceptibility Treat for 4--6 weeksInfective endocarditis, native valveVancomycin or daptomycin 6 mg/kg/dose IV once daily for 6 weeksVancomycin 30--60 mg/kg/day IV in 2--3 doses for 4--6 weeks Alternative therapies: daptomycin 10 mg/kg/day IV once daily for 4--6 weeks or TMP/SMX + clindamycinInfective endocarditis, prosthetic valveVancomycin IV + rifampin 300 mg PO/IV for ≥6 weeks + gentamicin 1 mg/kg/dose IV q8h for 2 weeksVancomycin 30--60 mg/kg/day IV in 2--3 doses for ≥6 weeks + rifampin 900--1200 mg IV or orally in  2--3 doses for ≥6 weeks and gentamicin 3/mg/kg/day IV or IM in 1--2 doses for 2 weeksInfective endocarditis, right-sidedVancomycin 15 mg/kg q12h for 6 weeks or daptomycin ≥6 mg/kg/day for 4--6 weeks if patient has renal impairment, sustained bacteremia for \>7 days, infection with a VISA strain Optional addition of short-term gentamicin to vancomycin Alternative option: vancomycin + rifampinInfective endocarditis, left-sidedVancomycin 15 mg/kg q12h for 4--6 weeks with early and careful attention to culture results Switch to high-dose daptomycin (10 mg/kg/day) if no response to vancomycin and isolate is susceptible Optional addition of short-term gentamicin to vancomycin Alternative option: vancomycin + rifampinPersistent bacteremia, despite vancomycin treatmentIf isolate is susceptible, high-dose daptomycin (10 mg/kg/day) + another agent^a^ If isolate has reduced susceptibility to vancomycin and daptomycin, options for monotherapy or combination therapy are quinupristin/dalfopristin 7.5 mg/kg/dose IV q8h, linezolid 600 mg PO/IV bid, or telavancin 10 mg/kg/dose IV odDaptomycin 10 mg/kg/day if isolates susceptible, possibly in combination with another agent (e.g., gentamicin, rifampicin, linezolid, a beta-lactam, or trimethoprim-sulfamethoxazole) Options for agents with reduced susceptibility to daptomycin or vancomycin, including quinupristin/dalfopristin, linezolid, or telavancinAdapted from US and International guidelines and recommendations found in Garau et al. \[[@CR60]\], Gould et al. 2011 \[[@CR59]\], Gould et al. 2012 \[[@CR62]\], Habib et al. \[[@CR63]\], and Liu et al. \[[@CR8]\]^a^Options include gentamicin 1 mg/kg IV q8h, rifampin 600 mg PO/IV daily or 300--450 mg PO/IV bid, linezolid 600 mg PO/IV bid, trimethoprim-sulfamethoxazole 5 mg/kg IV bid, or a beta-lactam antibiotic*Abbreviations*: *bid* twice daily, *ESC* European Society of Cardiology, *ESCMID* European Society of Clinical Microbiology and Infectious Diseases, *IDSA* Infectious Disease Society of America, *ISC* International Society of Chemotherapy, *IM* intramuscular, *IV* intravenous, *MRSA* methicillin-resistant *S. aureus*, *od* once daily, *PO* orally, *q8h*/*q12h* every 8/12 h, *TMP*/*SMX* trimethoprim/sulfamethoxazole, *VISA* vancomycin-intermediate *S. aureus*

Although vancomycin is the first-line antibiotic for MRSA bacteremia treatment, it has a relatively slow onset of bactericidal activity and poorly penetrates some tissues \[[@CR68]\]. While US guidelines recommend a fixed dose, European guidelines advise dosing vancomycin based on the trough plasma concentration (C~min~) \[[@CR62]\] with the goal to achieve a vancomycin area under the curve to minimum inhibitory concentration (MIC) ratio ≥400 for as long as possible throughout the 24-h dosing interval \[[@CR10]\]. However, recent evidence suggests C~min~ is not an accurate surrogate for 24-h vancomycin exposure, underestimating the area under the curve by up to 25% \[[@CR65]\]. In an analysis of MRSA bacteremia cases that received vancomycin, those who achieved a C~min~ of 15 to 20 mg/L within 72 h had a significantly lower rate of vancomycin failure compared with lower C~min~ values, but 40% of patients who had a C~min~ in the recommended range still did not \[[@CR68]\]. This may reflect the observed slow increase in the MIC (MIC creep) of vancomycin from the 1990s to the present, whereby higher doses are needed to maintain efficacy \[[@CR15]\]. Reports conflict on the correlation between vancomycin MICs \>1.5 mg/L and treatment failure in MRSA bacteremia \[[@CR69], [@CR70]\]. Additionally, individual studies may be affected by the method used to determine MIC (Etest or broth microdilution) or by duration of storage of isolates \[[@CR71]\]. Another concern of using higher doses of vancomycin is the potential for nephrotoxicity \[[@CR68]\], a risk factor for mortality in SAB \[[@CR72]\]. In a recent meta-analysis, continuous infusion of vancomycin was associated with less risk of nephrotoxicity compared to intermittent infusion, but no significant difference was found for mortality \[[@CR73]\]. However, Echeverria-Esnal et al. \[[@CR74]\] highlight factors that affect vancomycin-induced nephrotoxicity not considered in the individual studies, and suggest a multicenter randomized trial is needed to resolve the inconsistencies.

Daptomycin is considered an alternative first-line agent for MRSA bacteremia \[[@CR64]\], but MICs for vancomycin and daptomycin are correlated \[[@CR59], [@CR65]\], and up to 15% of heterogenous vancomycin-intermediate *S. aureus* isolates are also nonsusceptible to daptomycin \[[@CR65]\]. Furthermore, some studies suggest prior vancomycin failure is correlated with the acquisition of heteroresistance and reduced success of daptomycin therapy \[[@CR12], [@CR15], [@CR16]\]. Thus, higher doses of daptomycin (8--10 mg/kg) may be required for complicated or persistent MRSA bacteremia \[[@CR65]\]. Teicoplanin is another option for patients who are refractory to vancomycin; however, it is unavailable in some markets, including the US \[[@CR64]\]. It is approved by the European Medicines Agency for use in bacteremia associated with several Gram-positive infections, and is considered as effective and safe as vancomycin in treating healthcare-associated MRSA bacteremia \[[@CR75]\].

Given the limitations of currently approved treatments, other options are being developed. Vaccines targeting one or more *S. aureus* antigens have had minimal success to date and are reviewed elsewhere \[[@CR76]\]. Several studies have evaluated alternative antibacterials, including ceftaroline, linezolid, and quinupristin/dalfopristin (Q/D), although none have been approved for treatment of MRSA bacteremia \[[@CR64]\]. Ceftaroline is indicated for treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by *S. aureus*, but is often used off-label to treat SAB. A recent multicenter study found that approximately 70% of patients with MRSA bacteremia experienced clinical success when ceftaroline was used as a salvage therapy alone or in combination with another antistaphylococcal antibiotic \[[@CR77]\]. Clinical trials of ceftaroline compared to other MRSA bacteremia antimicrobials are still needed. Linezolid, indicated for pneumonia and complicated and uncomplicated skin and skin structure infections caused by *S. aureus*, was effective as a salvage therapy for MRSA bacteremia \[[@CR78], [@CR79]\]. It is bacteriostatic against staphylococci, while the other treatments are bactericidal. Quinupristin/dalfopristin is indicated for treatment of complicated skin and skin structure infections (cSSSI) caused by MSSA, but is known to have in vitro activity against MRSA. In a study using Q/D as salvage therapy for 12 patients with MRSA or methicillin-resistant *S. epidermis* infections that did not respond to vancomycin, five of seven MRSA bacteremic patients showed eradication of the bacteria \[[@CR80]\]. Telavancin is approved for use in Gram-positive cSSSI and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), and it is currently being evaluated for treatment of *S. aureus* bacteremia in a phase 3 trial (NCT02208063). In the clinical trials comparing telavancin to vancomycin, clinical cure rates for patients with cSSSI or HABP/VABP with baseline MRSA bacteremia were 61.5 and 52.4% for telavancin-treated patients and 50.0 and 37.5% in vancomycin-treated patients, respectively \[[@CR81]\]. Trimethoprim/sulfamethoxazole has also been suggested as an alternative treatment; however, it failed to meet noninferiority criteria compared with vancomycin in several trials of severe MRSA infections, including SAB \[[@CR64], [@CR82]\].

Combination therapy is another option being explored. Davis et al. \[[@CR83]\] compared vancomycin plus flucloxacillin to vancomycin alone in 60 MRSA bacteremia patients. Duration of bacteremia was reduced by 1 day and fewer combination therapy patients had persistent bacteremia at 3 and 7 days. Combination of daptomycin and ceftaroline retained a bactericidal effect on isolates that had increased daptomycin MICs \[[@CR84]\]. A phase 3 trial investigating β-lactam antibiotics given with daptomycin or vancomycin for MRSA bacteremia is ongoing (NCT02365493). Certain patients with IE may also benefit from combination of vancomycin or daptomycin with rifampin or an aminoglycoside. Although there are no definitive studies supporting its use, the addition of short-term gentamicin or rifampin is recommended in patients with prosthetic valve or left-sided disease \[[@CR8], [@CR60]\]; however, the European Society of Cardiology recommends against the use of an aminoglycoside in *S. aureus* native valve IE due to increased renal toxicity \[[@CR63]\]. Rifampin is bactericidal and can penetrate biofilms; however, it should not be used alone due to high potential to induce resistance \[[@CR8]\]. Any benefits of combination therapies should be carefully weighed against the probable effects on the intestinal microbiota, development of multidrug-resistant microorganisms, and possibly defying the protocols established by antimicrobial stewardship programs.

Transmission prevention strategies {#Sec7}
==================================

All healthcare personnel interacting with an MRSA-infected or -colonized person should use contact precautions to limit spread between patients \[[@CR85]\]. This means putting the MRSA-infected patient into a single or private room, and wearing gowns and gloves when entering the patient's room and removing them before exiting \[[@CR85]\]. Since MRSA colonization can be persistent, contact precautions should be used throughout an infected person's hospitalization (even after they have recovered from the MRSA infection) and with any person with a history of MRSA infection \[[@CR85]\]. Ideally, healthcare facilities should have a system in place to alert them to the readmission or transfer of an MRSA-infected patient, so appropriate controls can be put in place on their arrival \[[@CR85]\]. Hospital-wide hand hygiene campaigns have also greatly contributed to reduction of MRSA infections (reviewed in \[[@CR86]\]).

Because MRSA can contaminate the environment, the rooms of MRSA-infected patients require strict disinfection of furniture, overbed tables, handrails, sinks, floors, and any healthcare equipment used during patient care (e.g., stethoscopes, thermometers, blood pressure cuffs) \[[@CR85]\]. Xenon-UV light alone or in combination with normal cleaning decreases the presence of MRSA and other pathogens on surfaces by up to 99% \[[@CR87]\]. Use of certain materials such as copper alloys in building design can also reduce the environmental burden and transmission of MRSA and other hospital-acquired pathogens \[[@CR88]\].

Hospitals with high rates of MRSA infection should implement an active surveillance program to identify asymptomatic MRSA carriers and targeted MRSA decolonization programs to reduce infection rates \[[@CR85]\]. Surveillance combined with prophylactic treatment has been very effective in reducing surgical site infections \[[@CR89]\]. These protocols may combine intranasal antibiotics such as mupirocin with an antiseptic body wash or preoperative antibiotics \[[@CR89]\]. Surveillance is the key, though, to prevent misuse and overuse of antibiotics \[[@CR89]\].

Conclusions {#Sec8}
===========

Although identification and prevention techniques have improved, MRSA remains a major healthcare issue. MRSA bacteremia can be challenging to manage, especially in patients at high risk of complications or in those with toxigenic or multidrug-resistant strains. Early identification of MRSA is an important step toward timely implementation of appropriate treatment. The development of new molecular and immunochromatographic testing technologies has the potential to dramatically shorten delays to diagnosis and treatment. In addition, novel antibiotic therapies are becoming available to provide effective alternatives for strains that have acquired resistance to existing drugs. While these advances do not preclude the need for vigilance and effective MRSA prevention strategies, they help mitigate some of the challenges associated with MRSA bacteremia treatment.

CT

:   Computed tomography

HABP/VABP

:   Hospital-acquired and ventilator-associated bacterial pneumonia

IE

:   Infective endocarditis

MIC

:   Minimum inhibitory concentration

MRI

:   Magnetic resonance imaging

MRSA

:   Methicillin-resistant *Staphylococcus aureus*

MSSA

:   Methicillin-sensitive *Staphylococcus aureus*

PCR

:   Polymerase chain reaction

PFGE

:   Pulsed field gel electrophoresis

PSM

:   Phenol-soluble modulin

PVL

:   Panton-Valentine leukocidin

Q/D

:   Quinupristin/dalfopristin

SAB

:   *Staphylococcus aureus* bacteremia

SCC

:   Staphylococcal chromosomal cassette

TMP/SMX

:   Trimethoprim/sulfamethoxazole

TSST1

:   Toxic shock syndrome toxin-1

VISA

:   Vancomycin-intermediate *Staphylococcus aureus*
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